Papillary fibroelastoma in the left atrium.
Papillary fibroelastoma in the left atrium. Proc (Bayl Univ Med Cent). 2019 Apr;32(2):247-248 Authors: Roberts CS, Carry MM, Choi JW, Grayburn PA, Roberts WC Abstract Described herein is a 71-year-old woman with previous angina pectoris who suddenly developed slurred speech and right-arm weakness. She was found to have significant coronary narrowing, a small mass in the left atrium attached to the endocardium near the orifice of the appendage, and multifocal punctate cerebral lesions in the distribution of the left middle cerebral artery. The left atrial mass was excised and confirmed to be a papillary fibroelastoma. Coronary bypass was also performed. It is believed that fibrin thrombus developed within the fronds of the fibroelastoma and embolized to the brain. Such lesions in the left atrium are exceedingly uncommon. She had no further emboli events. PMID: 31191142 [PubMed]
New data from a second EXTEND-IA TNK (tenecteplase) trial clarify the optimum dose of the bolus thrombolytic for use in ischemic stroke, for which enthusiasm is growing.Medscape Medical News
Many commonly used medical devices, such as catheters, cardiopulmonary bypass systems, and endovascular grafts, are intended to come in contact with circulating blood. Therefore, these devices require an assessment for hemocompatibility risks such as hemolysis and thrombosis prior to submitting to a regulatory agency for market approval. The testing required for the evaluation of these specific endpoints depends on the exposure type and duration of the specific medical device under focus, and the guidance is captured in Table 1 of ISO 10993-4 Biological evaluation of medical devices - Part 4: Selection of tests for interac...
Abbott Laboratories is facing a Class I Recall of its coronary dilation catheters. The Abbott Park, IL-based company said that âcertain lotsâ of the NC Trek RX Coronary Dilatation Catheter would be impacted by the recall. According to FDAâs website the firm field personnel and Affiliates directly contacted the first customers beyond the firm's control via phone, email, or personal visit to facilitate rapid notification, Jan. 29, 2020. The "URGENT MEDICAL DEVICE RECALL" Notification informed customers that specific lots of its Coronary Dilatation Catheters with...
ConclusionHigh index of suspicion for thrombophilic disorders is required in postpartum patients presenting with respiratory distress as prompt diagnosis and urgent intervention can save patient’s life.
We thank Takagi et al for their additional analyses related to the systematic review we reported.1 Abdominal aortic aneurysm (AAA) size has previously been shown to be strongly correlated with intraluminal thrombus (ILT) volume and we agree this is an important confounding factor when examining the association betwe en ILT volume and AAA rupture.2 We therefore performed a subanalysis that included studies that matched for AAA size.1 That analysis actually included a total of 181 participants, not 77 as stated by Takagi et al.
We read with great interest a systematic review and meta-analysis by Singh et al1 of the relation of volume of intramural thrombus (IMT) to rupture of abdominal aortic aneurysm (AAA). The authors1 identified greater volume of IMT in ruptured AAA (RAAA) than in intact AAA (IAAA) (finding A) and no difference in IMT volume between RAAA and IAAA in patients matched for AAA dia meter or other covariates (finding B). The latter finding, however, was derived from only three studies2,3 enrolling 77 patients.
During the past decade, major advances in the treatment of acute deep venous thrombosis (DVT) have been achieved through the availability of oral direct thrombin/anti-Xa inhibitors and additional understanding gained in the use of pharmacomechanical catheter-directed thrombolysis in iliofemoral DVT through the results of the ATTRACT (Acute venous Thrombosis: Thrombus Removal with Adjunctive Catheter-directed Thrombolysis) prospective clinical trial. During this same period, Dr Henke and his colleagues have made important contributions to our understanding of the pathogenesis of DVT and, in particular, the role of inflammation in this process.
To determine the efficacy and safety of transjugular intrahepatic portosystemic shunt and portal vein recanalization (TIPS-PVR) for portal vein thrombosis (PVT) in patients without cirrhosis.
To characterize the creation of TIPS in patients with difficult anatomy due to portal venous thrombosis including indications for TIPS, technical feasibility, and adjunctive techniques.